Program overview
Context
Indication: Upper Urinary Tract Urothelial Carcinoma
Mechanism: Unknown
Modality: Unknown
Sponsor: RenJi Hospital
Watchlist Signal
RC48 Combined With Tislelizumab
RC48 Combined With Tislelizumab is flagged as watchlist signal because public records show timeline staleness, operational burden. This is a public-data monitoring signal, not a conclusion about clinical failure, regulatory noncompliance, or sponsor intent.
Scores
Risk-signal summary
Registry: 1/5
Timeline: 2/5
Recruitment burden: 2/5
Results availability: 0/5
Program risk: 2/5
Evidence
Public links
https://clinicaltrials.gov/study/NCT05912816
Linked trials
Trial-level signal details
| Trial | Status | Timeline | Results | Burden |
|---|---|---|---|---|
| NCT05912816 | Low Signal (RECRUITING) | primary_completion_date_past_signal | long_recruitment_duration_signal | Low Signal | rare_population_signal | strict_eligibility_signal |